RIT Biotech Company Limited is a newly established central-radiopharmacy aims at providing top quality services in Hong Kong. We commit and endeavor to serve the radiopharmaceutical industry by providing innovative radiopharmaceuticals and improving the quality service to the nuclear medicine and clinical oncology specialty. RIT Biotech is a holder of Authorized Seller of Poison (ASP) license granted by Department of Health, HKSAR. This license is granted under the condition that RIT Biotech fully complies with the requirement of “current Good Radiopharmacy Practices (Part A) in the preparation of radiopharmaceuticals” (cGRPP)– a guideline set out by European Association of Nuclear Medicine (EANM). With the cGRPP production and operation practice, we ensure the best quality assurance and meet all the requirements of Cap 138 Pharmacy & Poison Ordinance in Hong Kong. The cGRPP part A license for RIT Biotech is the first and the only license granted as of today in Hong Kong for SPECT / conventional radiopharmacy for nuclear medicine as well as clinical oncology.